146 citations
,
July 2003 in “Journal of the American Academy of Dermatology” In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.
114 citations
,
October 2006 in “Journal of the European Academy of Dermatology and Venereology” In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.
49 citations
,
November 2013 in “JAMA dermatology” This study found that topical clobetasol propionate cream was more effective than hydrocortisone cream in reducing hair loss surface area in children with patchy alopecia areata over 24 weeks, with no serious adverse effects.
13 citations
,
July 2011 in “Journal of Dermatological Treatment” This study found that topical pimecrolimus is as effective as clobetasol propionate for treating alopecia areata, with better tolerability in terms of side effects.
12 citations
,
August 2016 in “Biomedical Chromatography” This study developed and validated an HPLC-UV method for accurately quantifying clobetasol propionate in skin and hair follicles, demonstrating its application in in vitro permeation experiments.